Questions and answers on pre-clinical stage
About speaker(s)
Is a dog with ACVIM stage B2 chronic degenerative mitral valve disease always pre-clinical?
About speaker(s)
SYMPOSIUM 2016 INTRODUCTION
About speaker(s)
Conclusion to CardioSymposium 2011
About speaker(s) Marie-Laure Loubière – Ceva – Companion Animal Veterinary Services Director
Questions and Answers IV
About speaker(s)
Mineralocorticoid receptor antogonists: New therapeutic opportunities in chronic kidney diseases
About speaker(s)
Cardio-Renal syndromes: Lessons from Human pathophysiology
About speaker(s)
A rock and a hard place: cardiorenal syndrome in clinical canine veterinary patients
About speaker(s)
Questions and Answers III
About speaker(s)
Potential markers of cardiac remodeling and function
About speaker(s)
How to use biomarkers in cardiology ?
About speaker(s)
Biomarkers: what are the practical uses and what canbe expected in the coming years?
About speaker(s)
Questions and Answers II
About speaker(s)
The DELAY STUDY (DElay of Appearance of sYmptoms of canine degenerative mitral valve disease treated with Spironolactone and Benazepril)
About speaker(s)
Treatment of preserved cardiac function heart failure with an Aldosterone antagonist: the NHLBI TOPCAT Trial
About speaker(s)
Targeting the Aldosterone pathway in cardiovascular disease
About speaker(s)
Questions and Answers I
About speaker(s)
Where are we with aldosterone escape (Break-through) in 2011?
About speaker(s)
Aldosterone Receptor antagonists clinical interest: Beyond the “Aldosterone escape” concept
About speaker(s)
Introduction to Symposium
About speaker(s) Martin Mitchell – Ceva – Chief Sustainability Officer
Conclusion Symposium
About speaker(s) Marc Prikazsky – Ceva – CEO
Questions and Answers
About speaker(s)
Current clinical status and future directions for biomarkers in heart failure
About speaker(s)
Questions and Answers V
About speaker(s)
Principles of survival analysis illustrated by CEVA’s spironolactone trials
About speaker(s)
Efficacy of spironolactone in dogs with naturally occurring Myxomatous Mitral Valve Disease. (part II)
About speaker(s)
Efficacy of spironolactone in dogs with naturally occurring Myxomatous Mitral Valve Disease. (part I)
About speaker(s)
Questions and Answers IV
About speaker(s)
After RALES, the journey continues
About speaker(s)
Questions and Answers III
About speaker(s)
The proximate cause of heart failure: models, remodeling, and re-remodeling
About speaker(s)
Questions and Answers II
About speaker(s)
Mineralocorticoid receptor blockade: how experimental evidence supports the clinical benefit
About speaker(s)
Questions and Answers I
About speaker(s)
Overexpression of the mineralocorticoid receptors: pathophysiological consequences
About speaker(s)
Aldosterone and mineralocortoid receptors: expanding views from the kidney to the cardiovascular system.
About speaker(s)
Welcome Introduction Symposium
About speaker(s) Martin Mitchell – Ceva – Chief Sustainability Officer
